Surgical cytoreduction of the primary tumor reduces metastatic progression in a mouse model of prostate cancer

Cifuentes,Federico  F.; Valenzuela,Rodrigo  H.; Contreras,Héctor  R.; Castellón,Enrique  A.

doi:10.3892/or.2015.4319

Surgical cytoreduction of the primary tumor reduces metastatic progression in a mouse model of prostate cancer

Authors:
- Federico F. Cifuentes
- Rodrigo H. Valenzuela
- Héctor R. Contreras
- Enrique A. Castellón
View Affiliations

Affiliations: Laboratory of Molecular and Cellular Andrology, Physiology and Biophysics Program, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago 8380453, Chile
Published online on: October 1, 2015 https://doi.org/10.3892/or.2015.4319
Pages: 2837-2844
Copyright: © Cifuentes et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Metastatic prostate cancer (mPCa) is one of the most prevalent cancers in men worldwide. The main cause of death in these patients is androgen-resistant metastatic disease. Surgery of the primary tumor has been avoided in these patients as there is no strong evidence that supports a beneficial effect. From the biological point of view, it appears rational to hypothesize that the primary tumor may contribute to the establishment and growth of metastases. Considering this, we propose that cytoreductive surgery (CS) in advanced metastatic stage slows the progression of metastatic disease. To test this, we used a mouse model of resectable orthotopic prostate cancer (PCa) and performed CS. After surgery, metastases were smaller and less numerous in the treated mice; an effect that was observable until the end of the experiment. These results suggest that CS alone delays the progression of metastatic disease and that although this effect may be temporary, it may translate to prolonged survival, especially when used with adjuvant therapy.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Tangen CM, Hussain MH, Higano CS, Eisenberger MA, Small EJ, Wilding G, Donnelly BJ, Schelhammer PF, Crawford ED, Vogelzang NJ, et al: Improved overall survival trends of men with newly diagnosed M1 prostate cancer: A SWOG phase III trial experience (S8494, S8894 and S9346). J Urol. 188:1164–1169. 2012. View Article : Google Scholar : PubMed/NCBI
3	Valenca LB, Sweeney CJ and Pomerantz MM: Sequencing current therapies in the treatment of metastatic prostate cancer. Cancer Treat Rev. 41:332–340. 2015. View Article : Google Scholar : PubMed/NCBI
4	Chapin BF, Mcguire SE and Aparicio A: Is treatment of the primary tumor in metastatic prostate cancer justified? Eur Urol. 65:1067–1068. 2014. View Article : Google Scholar : PubMed/NCBI
5	Culp SH, Schellhammer PF and Williams MB: Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol. 65:1058–1066. 2014. View Article : Google Scholar
6	Swanson G, Thompson I, Basler J and Crawford ED: Metastatic prostate cancer - Does treatment of the primary tumor matter? J Urol. 176:1292–1298. 2006. View Article : Google Scholar : PubMed/NCBI
7	Qin XJ, Ma CG, Ye DW, Yao XD, Zhang SL, Dai B, Zhang HL, Shen YJ, Zhu Y, Zhu YP, et al: Tumor cytoreduction results in better response to androgen ablation - a preliminary report of palliative transurethral resection of the prostate in metastatic hormone sensitive prostate cancer. Urol Oncol. 30:145–149. 2012. View Article : Google Scholar
8	Nguyen DX: Tracing the origins of metastasis. J Pathol. 223:195–204. 2011. View Article : Google Scholar
9	Miyamoto DT, Sequist LV and Lee RJ: Circulating tumour cells - monitoring treatment response in prostate cancer. Nat Rev Clin Oncol. 11:401–412. 2014. View Article : Google Scholar : PubMed/NCBI
10	Sceneay J, Smyth MJ and Möller A: The pre-metastatic niche: Finding common ground. Cancer Metastasis Rev. 32:449–464. 2013. View Article : Google Scholar : PubMed/NCBI
11	Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, et al: VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 438:820–827. 2005. View Article : Google Scholar : PubMed/NCBI
12	Yu C, Shiozawa Y, Taichman RS, McCauley LK, Pienta K and Keller E: Prostate cancer and parasitism of the bone hematopoietic stem cell niche. Crit Rev Eukaryot Gene Expr. 22:131–148. 2012. View Article : Google Scholar : PubMed/NCBI
13	Hüsemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, Forni G, Eils R, Fehm T, Riethmüller G, et al: Systemic spread is an early step in breast cancer. Cancer Cell. 13:58–68. 2008. View Article : Google Scholar : PubMed/NCBI
14	Morgan SC and Parker CC: Local treatment of metastatic cancer - killing the seed or disturbing the soil? Nat Rev Clin Oncol. 8:504–506. 2011. View Article : Google Scholar : PubMed/NCBI
15	Cifuentes FF, Valenzuela RH, Contreras HR and Castellón EA: Development of an orthotopic model of human metastatic prostate cancer in the NOD-SCIDγ mouse (Mus musculus) anterior prostate. Oncol Lett. 10:2142–2148. 2015.
16	Demicheli R, Retsky MW, Hrushesky WJ, Baum M and Gukas ID: The effects of surgery on tumor growth: A century of investigations. Ann Oncol. 19:1821–1828. 2008. View Article : Google Scholar : PubMed/NCBI
17	Clamage DM, Sanford CS, Vander AJ and Mouw DR: Effects of psychosocial stimuli on plasma renin activity in rats. Am J Physiol. 231:1290–1294. 1976.PubMed/NCBI
18	Fisher B, Gunduz N, Coyle J, Rudock C and Saffer E: Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res. 49:1996–2001. 1989.PubMed/NCBI
19	Camphausen K, Moses MA, Beecken WD, Khan MK, Folkman J and O'Reilly MS: Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res. 61:2207–2211. 2001.PubMed/NCBI
20	Aguirre-Ghiso JA: Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 7:834–846. 2007. View Article : Google Scholar : PubMed/NCBI
21	Giancotti FG: Mechanisms governing metastatic dormancy and reactivation. Cell. 155:750–764. 2013. View Article : Google Scholar : PubMed/NCBI
22	Peinado H, Lavotshkin S and Lyden D: The secreted factors responsible for pre-metastatic niche formation: Old sayings and new thoughts. Semin Cancer Biol. 21:139–146. 2011. View Article : Google Scholar : PubMed/NCBI
23	Ghajar CM, Peinado H, Mori H, Matei IR, Evason KJ, Brazier H, Almeida D, Koller A, Hajjar KA, Stainier DY, et al: The perivascular niche regulates breast tumour dormancy. Nat Cell Biol. 15:807–817. 2013. View Article : Google Scholar : PubMed/NCBI
24	Antonyak MA and Cerione RA: Microvesicles as mediators of intercellular communication in cancer. Methods Mol Biol. 1165:147–173. 2014. View Article : Google Scholar : PubMed/NCBI
25	Uppal A, Ferguson MK, Posner MC, Hellman S, Khodarev NN and Weichselbaum RR: Towards a molecular basis of oligometastatic disease: Potential role of micro-RNAs. Clin Exp Metastasis. 31:735–748. 2014. View Article : Google Scholar : PubMed/NCBI
26	Tu SM and Lin SH: Prostate cancer stem cells. Clin Genitourin Cancer. 10:69–76. 2012. View Article : Google Scholar : PubMed/NCBI
27	Shackleton M, Quintana E, Fearon ER and Morrison SJ: Heterogeneity in cancer: Cancer stem cells versus clonal evolution. Cell. 138:822–829. 2009. View Article : Google Scholar : PubMed/NCBI
28	Ben-Eliyahu S: The promotion of tumor metastasis by surgery and stress: Immunological basis and implications for psychoneuroimmunology. Brain Behav Immun. 17(Suppl 1): S27–S36. 2003. View Article : Google Scholar : PubMed/NCBI
29	Neeman E and Ben-Eliyahu S: Surgery and stress promote cancer metastasis: New outlooks on perioperative mediating mechanisms and immune involvement. Brain Behav Immun. 30(Suppl): S32–S40. 2013. View Article : Google Scholar
30	Shultz LD, Goodwin N, Ishikawa F, Hosur V, Lyons BL and Greiner DL: Human cancer growth and therapy in immunodeficient mouse models. Cold Spring Harb Protoc. 2014:694–708. 2014. View Article : Google Scholar : PubMed/NCBI
31	Narasimhulu DM, Khoury-Collado F and Chi DS: Radical surgery in ovarian cancer. Curr Oncol Rep. 17:162015. View Article : Google Scholar : PubMed/NCBI
32	Faiena I, Singer EA, Pumill C and Kim IY: Cytoreductive prostatectomy: Evidence in support of a new surgical paradigm (Review). Int J Oncol. 45:2193–2198. 2014.PubMed/NCBI
33	Krabbe LM, Haddad AQ, Westerman ME and Margulis V: Surgical management of metastatic renal cell carcinoma in the era of targeted therapies. World J Urol. 32:615–622. 2014. View Article : Google Scholar : PubMed/NCBI
34	Neuman HB, Morrogh M, Gonen M, Van Zee KJ, Morrow M and King TA: Stage IV breast cancer in the era of targeted therapy: Does surgery of the primary tumor matter? Cancer. 116:1226–1233. 2010. View Article : Google Scholar : PubMed/NCBI
35	Verhagen PC, Schröder FH, Collette L and Bangma CH: Does local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? A systematic review. Eur Urol. 58:261–269. 2010. View Article : Google Scholar : PubMed/NCBI